CTOs on the Move

Lacerta Therapeutics

www.lacertatherapeutics.com

 
Clinical stage gene therapy company using a constellation of proprietary AAV vector technologies to develop novel treatments for central nervous system and lysosomal storage diseases
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Lacerta Therapeutics raised $30M on 08/09/2018

Similar Companies

InteKrin Therapeutics

InteKrin Therapeutics is a Los Altos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alberta Conservation Association

Alberta Conservation Association is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elastrin Therapeutics

Elastrin Therapeutics is a South Carolina-based biotech developing novel therapies to reverse cardiovascular disease. Its underlying technology was developed by Dr. Naren Vyavahare during the last 20 years at Clemson University, in collaboration with Dr. Charles Rice.

Medicinova

MediciNova, Inc., a development stage biopharmaceutical company, focuses on acquiring and developing small molecule therapeutics for the treatment of serious diseases for the United States market. The company’s principal product candidates include MN-166, an ibudilast-based drug candidate, which is in Phase I and Phase II clinical trials for the treatment of drug dependence and pain; and MN-221, a ß2 -adrenergic receptor agonist that has completed Phase II clinical trials for the treatment of acute exacerbations of asthma. It also has other product candidates in the clinical development for the treatment of acute exacerbations of asthma, multiple sclerosis and other central nervous system disorders, bronchial asthma, interstitial cystitis, solid tumor cancers, generalized anxiety disorders/insomnia, preterm labor, urinary incontinence, and thrombotic disorders. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California.

Mantra Bio

Mantra Bio is harnessing exosomes to deliver safe, highly targeted medicines. We are the creator of REVEAL™, an exosome engineering platform combining computational biology and lab automation to generate targeted exosome vehicles (TEVs) for a broad set of therapeutic areas.